Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
573 articles with Alexion Pharmaceuticals Inc.
- Anne-Marie Law becomes Chief Patient and Employee Experience Officer - - Aradhana Sarin, M.D., appointed as Chief Strategy and Business Officer -
4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase
Alexion Pharmaceuticals announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET.
Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis
Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Caelum Biosciences, Inc. (“Caelum”) has signed a strategic agreement with Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ: ALXN) to advance the development of CAEL-101 for light chain (AL) amyloidosis.
Shares of Fortress Biotech have skyrocketed more than 62 percent in premarket trading after its subsidiary Caelum Biosciences forged a deal worth up to more than $500 million with Alexion Pharmaceuticals.
Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS™ (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Study met primary objective of complete thrombotic microangiopathy (TMA) response
Boston-based Alexion’s Ultomiris (ravulizumab-cwvz) hit its primary objective in its Phase III study of complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS).
The Orphan Drug Act (ODA) was enacted on January 4, 1983. It was designed to encourage the development of drugs for rare diseases. The law was amended the following year to define rare diseases as ones that affect fewer than 200,000 people in the U.S. But it also included drugs that affect more t...
Following the release of the financial results, Alexion management will conduct a conference call and audio webcast at 8:00 a.m. Eastern Time
Alexion Pharmaceuticals today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 7:30 a.m., PT. A breakout question and answer session will immediately follow the formal presentation.
Alexion Pharmaceuticals and Stemline Therapeutics both secured FDA approval for their drugs.
Alexion Pharmaceuticals announced that management will present at the Goldman Sachs 11th Annual Healthcare CEO Conference in New York, NY on Thursday, January 3, 2019 at 8 a.m., ET
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
First Conference Presentation of Results for ALXN1210 in Patients on Soliris® (Eculizumab) at ASH
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISI’s Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.m., ET.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisse’s 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET.
Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to company’s growing pipeline
Nine abstracts accepted, including three oral presentations of ALXN1210 Phase 3 PNH data